New insight into how ‘tidying up’ enzymes work

New insight into how ‘tidying up’ enzymes work

11:36 AM, 7th June 2011
New insight into how ‘tidying up’ enzymes work
Binding orientation of dextromethorphan in the active site of P450 2D6 as derived from QM/MM minimization.

A new discovery about how molecules are broken down by the body, which will help pharmaceutical chemists design better drugs, has been made by researchers at the University of Bristol.

 

BRISTOL, UK: Working with Professor Jeremy Harvey and Professor Adrian Mulholland of Bristol’s School of Chemistry, Dr Julianna Olah, an EU Marie Curie Fellow in Bristol at the time, studied a class of enzymes - cytochromes P450 - which play an important role in removing drug molecules from the body.

 

When a tablet of medicine is taken, the active molecules get absorbed into the bloodstream through the gut and make their way around the body, including to the cells in which they are intended to act; however, it’s important they don’t stay in the body forever. Enzymes (biological catalysts) help break them down to facilitate excretion.

 

The cytochromes P450 are a very important class of these ‘tidying up’ enzymes which have evolved to deal with all ‘foreign’ compounds that do not get broken down as part of normal metabolism (that is, any compounds which are not proteins, carbohydrates or lipids).

 

Mainly situated in the liver, the P450 enzymes help remove drug molecules by adding oxygen to them. This process usually works smoothly, but for some molecules, it can lead to oxygenated variants that are toxic. Other molecules are also able to interfere with the normal function of the P450 enzymes.

 

For these reasons, it is important to be able to understand how a given new molecule, considered for use as a medicine, will react with these enzymes. The Bristol researchers aimed to provide this understanding by modeling the reaction mechanism for interaction between one specific drug (dextromethorphan, a component of some cough syrups) and one P450 variant.

 

Professor Jeremy Harvey said: “Our calculations showed that the outcome of the oxygen transfer process (that is, which part of dextromethorphan oxygen gets added to) is affected by three factors.

 

“The first is the way in which the molecule fits into the enzyme (‘docking’).  The second is the intrinsic ability of each part of the molecule to accept oxygen.  The third is how much each competing oxygen-delivery process is compatible with the shape of the enzyme pocket where the reaction occurs.

 

“While these first two factors were already known, the third was not.  This discovery can help pharmaceutical chemists design new drug molecules with a better understanding of how they will be broken down in the body.”

(C) University of Bristol News

 

 

0 Comments

Login

Your Comments (Up to 2000 characters)
Please respect our community and the integrity of its participants. WOC reserves the right to moderate and approve your comment.

Related News


£6 million to develop a new generation of composites

Existing fibre-reinforced polymer composites are known for their high strength and stiffness, which are used in applications from sporting goods to ...

Read more
Dow, Aksa to jointly manufacture carbon fibre and derivatives

The companies will jointly look to offer carbon fibre and derivatives to growing energy, transportation and infrastructure markets.   MIDLAND, ...

Read more
Scientists find new drug target in breast cancer

  Researchers have identified a new protein involved in the development of drug resistance in breast cancer which could be a target for new trea ...

Read more
Rhodia, Sibur form surfactants joint venture in Russia

  PARIS, FRANCE: Rhodia and Sibur will create a joint venture in specialty surfactants. It is expected, the new 50:50 joint venture will have a ...

Read more
BASF partners with research institutes to reduce crop loss in Africa

Four-year agreement to combat “invisible” Striga weed Partnership includes leading agricultural research institutes     ...

Read more
AkzoNobel, Quangxi CAVA to jointly build TiO2 plant in China

  AMSTERDAM, THE NETHERLANDS: AkzoNobel has partnered with Quangxi CAVA Titanium Industry Co Ltd in China, for the production and supply of tita ...

Read more
www.worldofchemicals.com uses cookies to ensure that we give you the best experience on our website. By using this site, you agree to our Privacy Policy and our Terms of Use. X